The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator assessments, subject questionnaires/assessments, photography, skin imaging, and reported adverse reactions.
Post-menopausal women (25 on HRT, 25 non HRT all must be post-menopausal)
Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.
Adult women aged 45-65 years.
Fitzpatrick skin types I-VI.
Non post-menopausal state.
Any uncontrolled systemic disease.
History of autoimmune connective tissue disease.
Current use of immunosuppressive medication.
Goldman, Butterwick, Fitzpatrick and Groff
Lead sponsor
L'Oreal
Collaborator